Corbus Pharmaceuticals Holdings Inc (CRBP)

In the past six months, Corbus Pharmaceuticals reported Q3 2025 financial results with an increased net loss. They presented positive CRB-701 data at ESMO 2025 and completed a public offering, raising approximately $73.8 million. Positive Phase 1a results for CRB-913 were reported, and a Phase 1b study was initiated. The company plans to meet with the FDA regarding CRB-701 and expects to initiate a registrational study for CRB-701 by mid-2026, with 12-week CRB-913 obesity data expected in summer 2026. Over the past year, CRBP stock has traded between $20.56 and $4.64, with a share price of $8.01 as of February 4, 2026, representing a 29.30% decline.

As a clinical-stage biopharmaceutical company, Corbus Pharmaceuticals Holdings, Inc. does not generate revenue from commercial product sales. Its business model relies on capital market financing, and its financial performance is influenced by clinical trial progress, regulatory milestones, and capital market activities rather than seasonal consumer demand.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and obesity. Their pipeline includes CRB-701, an antibody-drug conjugate in Phase 1 trials for solid tumors; CRB-601, an anti-integrin monoclonal antibody for solid tumors; and CRB-913, a CB1 receptor inverse agonist for obesity, which has completed a Phase 1a study and initiated a Phase 1b study. The company, founded in 2009 and headquartered in Norwood, Massachusetts, has shifted its focus to oncology and obesity.

Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, Massachusetts, United States. The company manages multi-center Phase 1 and Phase 2 clinical trials for its drug programs across the U.S. and Europe.

Corbus Pharmaceuticals Holdings, Inc. maintains a positive reputation within the analyst community, with a "Moderate Buy" consensus rating. Positive events include robust Phase 1/2 data for CRB-701, a successful public offering, positive CRB-913 Phase 1a results, and FDA Fast Track designation for CRB-701. While the stock price has declined, this is common for clinical-stage biotechs.

Corbus Pharmaceuticals Holdings, Inc. is a publicly held company traded on the Nasdaq. Institutional investors hold a significant majority of the shares, with major shareholders including Cormorant Asset Management, Aberdeen Group Plc, and OrbiMed Advisors LLC. Hedge funds control approximately 24% of shares, and individual investors hold around 21.75%.